<DOC>
	<DOCNO>NCT01148576</DOCNO>
	<brief_summary>To investigate influence hepatic steatosis anti-viral effect entecavir chronic hepatitis B patient .</brief_summary>
	<brief_title>Influence Hepatic Steatosis Therapeutic Effect Entecavir Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Chronic hepatitis B ( CHB ) affect approximately 360 million person worldwide common cause liver disease affect 10 % general population China . Hepatic steatosis main hepatic presentation non- alcoholic fatty liver disease become another important liver disorder China worldwide economic development . It would expect hepatic steatosis might occur CHB patient recent study show frequency steatosis CHB range 27 % 51 % . However , effect steatosis anti-viral treatment CHB patient still vague . The aim RCT investigate effect steatosis therapeutic effect entecavir chronic hepatitis B patient . We compare anti-viral effect entecavir among four group : CHB group entecavir therapy , CHB + steatosis group entecavir therapy , CHB + steatosis group entecavir + essentiale therapy CHB + steatosis group entecavir + vitamin E therapy . The speculated point set 3 month , 12 month 15 month . Liver biopsy carry begin 12th month . Other serum biochemical viral marker record well CT ultrasound scan repeat .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Essential 303 forte</mesh_term>
	<criteria>Patients diagnose chronic hepatitis B infection hepatic steatosis 1 . CHB infection HBVDNA ≥ 1×105 copies/ml； HBeAg positive ； ALT 210 time upper limit level 2. hepatic steatosis According `` Guidelines assessment management nonalcoholic fatty liver disease AsiaPacific region : executive summary '' , test CT scan B ultrasound confirmation liver biopsy ( portion patient ) 1. receive antiviral treatment study 2. hepatoxic drug treatment , 3. consume alcohol regularly excessively , 4. diagnosed cirrhosis , antiHCV antiDelta positive patient , 5. diagnose autoimmune metabolic liver diseases 6. wilson 's disease , PBC , PSC , IBD diseases may influence process effect therapy 7. pregnant , mental disorder receive antiviral treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>hepatic steatosis , chronic hepatitis B , entecavir</keyword>
</DOC>